الوصف

Validation experiments for the SIRT1-DNMT1 deacetylation pathway in additional prostate cancer cell models treated with melatonin.

Figure 35

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 35: Validation experiments for the SIRT1-DNMT1 deacetylation pathway in additional prostate cancer cell models treated with melatonin.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Validation experiments for the SIRT1-DNMT1 deacetylation pathway in additional prostate cancer cell models treated with melatonin." />
  <figcaption>Figure 35. Validation experiments for the SIRT1-DNMT1 deacetylation pathway in additional prostate cancer cell models treated with melatonin.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

أدلة ذات صلة

Melatonin لـ اضطراب الإيقاع اليوماوي

التقييم A · 176 دراسات